Skip to main content
NKMAX Co., Ltd. logo

NKMAX Co., Ltd. — Investor Relations & Filings

Ticker · 182400 ISIN · KR7182400002 KO Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2020-06-22 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 182400

About NKMAX Co., Ltd.

https://nkmax.com/

NKMAX Co., Ltd. is a biotechnology company focused on developing immune-based solutions centered on Natural Killer (NK) cells. The company's primary focus is the development of adoptive cell therapies to treat incurable diseases, including cancer, autoimmune disorders, and neurodegenerative conditions. Its portfolio includes anti-cancer immunotherapy treatments and other biological products. In addition to therapeutics, NKMAX develops and markets a precision diagnostic test that measures NK cell activity. The company also manufactures and supplies specialized reagents, such as high-quality recombinant proteins and antibodies, for biotechnology research, as well as a line of health functional foods designed to support the immune system.

Recent filings

Filing Released Lang Actions
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from NKMax regarding the amendment of a previously submitted report on 'Stock Option Grants' (주식매수선택권 부여에 관한 신고). It details the correction of fair value calculations for stock options granted to executives and employees. Since this is a formal regulatory disclosure regarding capital structure and employee compensation instruments (stock options), and it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Remuneration Information' (which is typically for annual proxy statements), it falls under the general regulatory filing category.
2020-06-22 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. This document type is used to report significant changes in share ownership by major shareholders (often referred to as the '5% rule' filing). In the provided classification schema, this falls under 'Major Shareholding Notification' (MRQ).
2020-06-17 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to executives and employees, including the number of shares, exercise price, and valuation methodology. Since this is a specific regulatory disclosure regarding capital structure and equity-based compensation that does not fit into the other specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes), it is classified as a Regulatory Filing.
2020-06-17 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details the changes in share ownership by an institutional investor (Korea Investment Value Asset Management) in a specific company (NKMax). This type of filing is a mandatory disclosure for significant shareholding changes and falls under the 'Major Shareholding Notification' category.
2020-06-02 Korean
증권발행결과(자율공시)(제10회차 CB)
Capital/Financing Update Classification · 100% confidence The document is a formal announcement regarding the results of a securities issuance (specifically a convertible bond, or CB). It details the issuance amount, payment date, and the nature of the security. This falls under the category of capital and financing updates, as it reports on the completion of a fundraising activity.
2020-05-27 Korean
[기재정정]주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) filed with the Financial Services Commission in South Korea, specifically detailing the 'Decision to Issue Convertible Bonds' (전환사채권 발행결정). It includes detailed terms of the issuance, such as interest rates, conversion prices, put/call options, and a list of investors. This type of filing is a standard regulatory disclosure for capital raising activities. Since it is a formal report on capital structure changes and financing, it falls under the 'Capital/Financing Update' category.
2020-05-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.